Comparative Angiogenic Effect of Microencapsulated Celecoxib in PLGA v/s non-Encapsulated in an in vivo Angiogenesis Assay

Tweet about this on TwitterShare on FacebookEmail this to someoneShare on Google+

Ignacio Roa; Ricardo Poblete Cortés; Mario Salinas Sanhueza; Daniel Tobar Ugalde; Alondra Donoso & Carlos Rosas


Angiogenesis is the process of blood vessel formation from previously formed ones. There are several factors involved in the process, as well as agents capable of modulating different stages of it. Although, it has been observed that Celecoxib is capable of inhibiting angiogenesis in different models, the potential antiangiogenic capacity of this agent has not yet been observed when it is microencapsulated in PLGA. Fertilized eggs were incubated and at 48 hours they were divided into 4 groups to be instilled with PBS (control), PLGA, Celecoxib 1000ppm or Celecoxib 1000 ppm + PLGA. A blood vessel count was performed at 48, 72 and 96 hours after application of the solution to be studied. The results show that both Celecoxib and Celecoxib + PLGA re- duce blood vessels, maintaining the same effect at 48, 72 and 96 hours and there are no significant differences between the two treatments. This could be explained by the concentration of Celecoxib used or the time frame analyzed, being able to find differences after this time range or with different concentrations.

KEY WORDS: Angiogenesis; Microencapsulation; Celecoxib; PLGA.

How to cite this article

ROA, I.; POBLETE, C. R.; SALINAS, S. M.; TOBAR, U. D.; DONOSO, A. & ROSAS, C. Comparative angiogenic effect of microencapsulated celecoxib in plga v/s non-encapsulated in an in vivo angiogenesis assay. Int. J. Morphol., 40(2):420-424, 2022.